BHWM
TEVA icon

Beaird Harris Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Beaird Harris Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324 Hold
10
– – ﹤0.01% 629
2026
Q1 		$288 Hold
10
– – ﹤0.01% 607
2025
Q4 		$298 Sell
10
-60
-86% -$1.48K ﹤0.01% 626
2025
Q3 		$1.41K Buy
+70
New +$1.23K ﹤0.01% 544

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Beaird Harris Wealth Management's TEVA Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 10 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Beaird Harris Wealth Management first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.41K in Q3 2025. 103 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Beaird Harris Wealth Management held 10 shares of Teva Pharmaceuticals worth $324 as of Q2 2026.
  • Beaird Harris Wealth Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #629 holding.
  • Beaird Harris Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Beaird Harris Wealth Management's Teva Pharmaceuticals position peaked at $1.41K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.